Figure 5From: Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy Red bone marrow (RBM) dose versus the percentage difference in AD tumor /AD RBM for 90 Y compared to 177 Lu. A positive difference represents a higher tumor-to-RBM dose ratio in 90Y.Back to article page